Drugs / QIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06622590 | Oct 2024 → Jan 2025 overdue | influenza | Institute of Medical Biology, Chinese Academy of Medical Sciences | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06622590 ↗ |
| Modality | Vaccine | “Quadrivalent Influenza Virus Split Vaccine” NCT06622590 ↗ |